AstraZeneca PLC Plans Dividend of GBX 77.60 (LON:AZN)

AstraZeneca PLC (LON:AZN) announced a dividend on Thursday, July 25th, Upcoming.Co.Uk reports. Stockholders of record on Thursday, August 8th will be paid a dividend of GBX 77.60 ($1.00) per share by the biopharmaceutical company on Monday, September 9th. This represents a dividend yield of 0.64%. The ex-dividend date is Thursday, August 8th. The official announcement can be viewed at this link.

AstraZeneca Trading Up 0.9 %

Shares of AZN opened at £121.66 ($157.35) on Friday. AstraZeneca has a twelve month low of GBX 9,461 ($122.36) and a twelve month high of £127.04 ($164.30). The firm has a market capitalization of £188.57 billion, a P/E ratio of 3,865.38, a price-to-earnings-growth ratio of 0.97 and a beta of 0.16. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 92.51. The stock’s fifty day simple moving average is £122.72 and its 200 day simple moving average is £112.83.

Analyst Ratings Changes

A number of equities analysts have recently commented on AZN shares. Barclays restated an “overweight” rating and issued a £125 ($161.67) price objective on shares of AstraZeneca in a report on Monday, April 8th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, June 4th. Jefferies Financial Group increased their price objective on shares of AstraZeneca from GBX 71 ($0.92) to GBX 74 ($0.96) and gave the stock a “hold” rating in a research report on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a £110 ($142.27) target price on shares of AstraZeneca in a report on Tuesday, June 18th. Finally, Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of £105.53 ($136.49).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.